Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Tumors|Leukemia
Interventions: DRUG: Bosutinib (SKI-606)
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer